These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27653831)

  • 1. Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus in mice.
    Zhou C; Lehar S; Gutierrez J; Rosenberger CM; Ljumanovic N; Dinoso J; Koppada N; Hong K; Baruch A; Carrasco-Triguero M; Saad O; Mariathasan S; Kamath AV
    MAbs; 2016; 8(8):1612-1619. PubMed ID: 27653831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
    Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
    MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
    Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
    MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti-
    Cai H; Yip V; Lee MV; Wong S; Saad O; Ma S; Ljumanovic N; Khojasteh SC; Kamath AV; Shen BQ
    Drug Metab Dispos; 2020 Nov; 48(11):1161-1168. PubMed ID: 32839277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained activity of novel THIOMAB antibody-antibiotic conjugate against Staphylococcus aureus in a mouse model: Longitudinal pharmacodynamic assessment by bioluminescence imaging.
    Zhou C; Cai H; Baruch A; Lewin-Koh N; Yang M; Guo F; Xu D; Deng R; Hazenbos W; Kamath AV
    PLoS One; 2019; 14(10):e0224096. PubMed ID: 31661493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti-
    Peck M; Rothenberg ME; Deng R; Lewin-Koh N; She G; Kamath AV; Carrasco-Triguero M; Saad O; Castro A; Teufel L; Dickerson DS; Leonardelli M; Tavel JA
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910894
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonclinical toxicology development of a novel antibody antibiotic conjugate for treating invasive Staphylococcus Aureus infections.
    Stagg NJ; Katavolos P; Achilles Poon K; Zhong S; Ljumanovic N; Kamath A; Cai H; Carrasco-Triguero M; Halpern W
    Toxicol Appl Pharmacol; 2022 Jan; 435():115811. PubMed ID: 34896194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections.
    Mariathasan S; Tan MW
    Trends Mol Med; 2017 Feb; 23(2):135-149. PubMed ID: 28126271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.
    Xiao XM; Xiao YH
    Acta Pharmacol Sin; 2008 Oct; 29(10):1253-60. PubMed ID: 18817632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus.
    Lehar SM; Pillow T; Xu M; Staben L; Kajihara KK; Vandlen R; DePalatis L; Raab H; Hazenbos WL; Morisaki JH; Kim J; Park S; Darwish M; Lee BC; Hernandez H; Loyet KM; Lupardus P; Fong R; Yan D; Chalouni C; Luis E; Khalfin Y; Plise E; Cheong J; Lyssikatos JP; Strandh M; Koefoed K; Andersen PS; Flygare JA; Wah Tan M; Brown EJ; Mariathasan S
    Nature; 2015 Nov; 527(7578):323-8. PubMed ID: 26536114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
    Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8-fusion protein (Hla-MntC-SACOL0723) immunoconjugates.
    Ahmadi K; Aslani MM; Pouladfar G; Faezi S; Kalani M; Pourmand MR; Ghaedi T; Havaei SA; Mahdavi M
    IUBMB Life; 2020 Feb; 72(2):226-236. PubMed ID: 31573748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic and pharmacodynamic evaluation of iclaprim activity against wild-type and corresponding thymidine kinase-deficient Staphylococcus aureus in a mouse abscess model.
    Huang DB
    J Med Microbiol; 2019 Jan; 68(1):77-80. PubMed ID: 30451652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly Efficient Synthesis of a Staphylococcus aureus Targeting Payload to Enable the First Antibody-Antibiotic Conjugate.
    Linghu X; Segraves NL; Abramovich I; Wong N; Müller B; Neubauer N; Fantasia S; Rieth S; Bachmann S; Jansen M; Sowell CG; Askin D; Koenig SG; Gosselin F
    Chemistry; 2018 Feb; 24(12):2837-2840. PubMed ID: 29164727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
    Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
    Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model.
    Hirai J; Hagihara M; Kato H; Sakanashi D; Nishiyama N; Koizumi Y; Yamagishi Y; Suematsu H; Hanaki H; Mikamo H
    J Infect Chemother; 2016 Jun; 22(6):387-94. PubMed ID: 27029221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus.
    Yarlagadda V; Konai MM; Paramanandham K; Nimita VC; Shome BR; Haldar J
    Int J Antimicrob Agents; 2015 Oct; 46(4):446-50. PubMed ID: 26188396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.